Cited by 133Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 125 of the 126 references it cites were found in a registry or an index.

Immunotherapy comes of age: Immune aging & checkpoint inhibitors

Elias, Rawad, Karantanos, Theodoros, Sira, Elizabeth, Hartshorn, Kevan L.·2017·Journal of Geriatric Oncology

DOI 10.1016/j.jgo.2017.02.001

Open this paper in CoChat — free account

Abstract

Immune checkpoint inhibitors (ICIs) are based on the understanding that there are multilayered checks and balances which can be manipulated to unleash already existing, but paralyzed, immune responses to cancer. These agents are safer and more efficacious than classic cytotoxic drugs making them a very attractive therapeutic option, especially in older adults. Current available data do not suggest significant age-associated differences in the clinical profile of ICIs. It must be noted, however, that there is still relatively little information on the use of ICIs in adults over 75years of age and aging is associated with a decline in the immune system or "immunosenescence" which theoretically can reduce the efficacy of these immune based therapies. In this paper, we review the mechanism of action of ICIs, current clinical data on their use in older adults, and age-associated immune changes that might have a direct impact on their activity in this population. We chose to focus on mainly adaptive cellular immunity, and especially on components of the immune system that are implicated directly in the immune checkpoint process.

Integrity signals

Registry

Crossref · 10.1016/j.jgo.2017.02.001

Cites

125 of 125 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981

Show all 126 references

Research works printed but not linked: 1

Singh, 2016, FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers. | 2016 ASCO Annual Meeting | Abstracts | Meeting Library, J Clin Oncol, 34

Sorted by citations

Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?
Fulop, T., Larbi, A., Dupuis, G., Le Page, A., Frost, E. H., Cohen, A. A., Witkowski, J. M., & Franceschi, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01960 · Cited by 1,364
How the ageing microenvironment influences tumour progression
Fane, M., & Weeraratna, A. T. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0222-9 · Cited by 849
Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention
Aiello, A., Farzaneh, F., Candore, G., Caruso, C., Davinelli, S., Gambino, C. M., Ligotti, M. E., Zareian, N., & Accardi, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02247 · Cited by 693
The integration of inflammaging in age-related diseases
Fülöp, T., Witkowski, J. M., Olivieri, F., & Larbi, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.09.003 · Cited by 368
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies
Nosaki, K., Saka, H., Hosomi, Y., Baas, P., de Castro, G., Reck, M., Wu, Y.-L. L. C., Brahmer, J. R., Felip, E., Sawada, T., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.07.004 · Cited by 292
Cancer and Aging: Two Tightly Interconnected Biological Processes
Berben, L., Floris, G., Wildiers, H. P. M. W., & Hatse, S. (2021) · Cancers · doi:10.3390/cancers13061400 · Cited by 253
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
Elias, R., Giobbie-Hurder, A., McCleary, N. J., Ott, P., Hodi, F. S., & Rahma, O. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0336-8 · Cited by 218
Immune checkpoint inhibitors and elderly people: A review
Daste, A., Domblides, C., Gross‐Goupil, M., Chakiba, C., Quivy, A., Cochin, V., de Monès, E., Larmonier, N., Soubeyran, P., & Ravaud, A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.044 · Cited by 194
Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly
Pereira, B. I., Xu, X., & Akbar, A. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583019 · Cited by 190
Immune Checkpoint Inhibitors in Real‐World Treatment of Older Adults with Non–Small Cell Lung Cancer
Muchnik, E., Loh, K. P., Strawderman, M. S., Magnuson, A. M., Mohile, S. G., Estrah, V., & Maggiore, R. J. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15750 · Cited by 116
Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer
van Holstein, Y., Kapiteijn, E., Bastiaannet, E., van den Bos, F., Portielje, J. E. A., & de Glas, N. A. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00697-2 · Cited by 114
Targeting immunosenescence and inflammaging: advancing longevity research
Nguyen, T. Q. T., & Cho, K. A. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01527-9 · Cited by 100
Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson’s Disease
Kuštrimović, N. Z., Marino, F., & Cosentino, M. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181009161048 · Cited by 74
The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study
Karantanos, T., Karanika, S., Seth, B., & Gignac, G. A. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1908-2 · Cited by 76
Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age
Saba, N. F., Blumenschein, G. R., Guigay, J., Licitra, L. F., Fayette, J., Harrington, K. J., Kiyota, N., Gillison, M. L., Ferris, R. L., Jayaprakash, V., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.06.017 · Cited by 68
Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications
Zhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 68
Clinical perspectives on the age-related increase of immunosuppressive activity
Salminen, A. (2022) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02193-4 · Cited by 57
Immunotherapy in older patients with cancer
Granier, C., Gey, A., Roncelin, S., Weiss, L., Paillaud, É., & Tartour, É. (2020) · Biomedical Journal · doi:10.1016/j.bj.2020.07.009 · Cited by 58
Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice
Zhang, C., Lei, L., Yang, X., Ma, K., Zheng, H., Su, Y., Jiao, A., Wang, X., Liu, H., Zou, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002809 · Cited by 50
The use of immunotherapy in older patients with advanced non-small cell lung cancer
Tagliamento, M., Frélaut, M., Baldini, C., Naigeon, M., Nencioni, A., Chaput, N., & Besse, B. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102394 · Cited by 48
Innate Immunity and Influenza A Virus Pathogenesis: Lessons for COVID-19
Hartshorn, K. L. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.563850 · Cited by 48
Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Yan, X., Tian, X., Wu, Z., & Han, W. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01671 · Cited by 45
Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients
Perrotta, F., Rocco, D., Vitiello, F., Palma, R. D., Guerra, G., Luca, A. D., Navani, N., & Bianco, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092258 · Cited by 43
Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study
Ridolfi, L., Rosa, F. D., Petracci, E., Tanda, E. T., Marra, E., Pigozzo, J., Marconcini, R., Guida, M., Cappellini, G. C. A., Gallizzi, G., et al. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.12.012 · Cited by 40
CD48 is a key molecule of immunomodulation affecting prognosis in glioma
Zou, C., Zhu, C. Y., Guan, G., Guo, Q., Liu, T., Shen, S., Yan, Z., Xu, X., Lin, Z., Chen, L., et al. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s198762 · Cited by 36
Management of immunotherapy toxicities in older adults
Bhandari, S., Gill, A. S., Perez, C. A., & Jain, D. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.09.001 · Cited by 31
Hyperprogression, a challenge of PD-1/PD-L1 inhibitors treatments: potential mechanisms and coping strategies
Zhao, L.-P., Hu, J.-H., Hu, D., Wang, H., Huang, C.-G., Luo, R., Huang, X., Huang, X., Xie, T., & Lou, J.-S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112949 · Cited by 34
Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis
Huo, G., Liu, W., & Chen, P. (2023) · BMC Cancer · doi:10.1186/s12885-023-10605-y · Cited by 31
Patient Selection for Anti-PD-1/PD-L1 Therapy in Advanced Non-Small-Cell Lung Cancer: Implications for Clinical Practice
Califano, R., Lal, R., Lewanski, C. R., Nicolson, M. C., Ottensmeier, C. H. H., Popat, S., Hodgson, M. J., & Postmus, P. E. (2018) · Future Oncology · doi:10.2217/fon-2018-0330 · Cited by 31
Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis
Zhang, L., Sun, L., Yu, J., Shan, F., Zhang, K., Pang, X., Ma, C., Zhang, Y., Shen, M., Ma, S., et al. (2019) · BioMed Research International · doi:10.1155/2019/9853701 · Cited by 30
Efficacy of Anti-PD-1/PD-L1 Monotherapy or Combinational Therapy in Patients Aged 75 Years or Older: A Study-Level Meta-Analysis
Nie, R., Chen, G.-M., Wang, Y., Zhou, J., Duan, J., Zhou, Z., & Yuan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.538174 · Cited by 31
Age Associated Microbiome and Microbial Metabolites Modulation and Its Association With Systemic Inflammation in a Rhesus Macaque Model
Pallikkuth, S., Russell, K., Sirupangi, T., Méndez, R., Kvistad, D., Pahwa, R., Villinger, F. J., Banerjee, S., & Pahwa, S. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.748397 · Cited by 31
The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis
Li, P., Yang, X., Feng, Y., Wu, L., Ma, W., Ding, G., Wei, Y., & Sun, L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s165368 · Cited by 29
Endometrial cancer in the elderly: Characteristics, prognostic and risk factors, and treatment options
Forte, M., Cecere, S. C., Napoli, M. D., Ventriglia, J., Tambaro, R., Rossetti, S., Passarelli, A. M., Casartelli, C., Rauso, M., Alberico, G., et al. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104533 · Cited by 29
The effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages
Wu, Y. C., Ju, Q., Qian, B., Zhang, F., & Shi, H. M. (2017) · Oncotarget · doi:10.18632/oncotarget.23678 · Cited by 29
Immunotherapy in older patients with hepatocellular carcinoma
Lyu, N., Yi, J., & Zhao, M. D. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.024 · Cited by 29
Effect of age and sex on immune checkpoint expression and kinetics in human T cells
Reitsema, R. D., Cadena, R. H., Nijhof, S., Abdulahad, W. H., Huitema, M. G., Paap, D., Brouwer, E., Boots, A. M. H., & Heeringa, P. (2020) · Immunity & Ageing · doi:10.1186/s12979-020-00203-y · Cited by 28
Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: a systematic review and meta-analysis
Yao, J., Li, S., Bai, L., Chen, J., Ren, C., Liu, T., Qiu, J., & Dang, J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103081 · Cited by 28
Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics
Liu, W., Huo, G., & Chen, P. (2023) · BMC Cancer · doi:10.1186/s12885-023-10959-3 · Cited by 26
Toxicity in Older Patients with Cancer Receiving Immunotherapy: An Observational Study
Hoi, E. T. V., Trompet, S., van Holstein, Y., van den Bos, F., van Heemst, D., Codrington, H., Labots, G., Lohman, S., Özkan, A., Portielje, J. E. A., et al. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01114-z · Cited by 24
Targeting immunosenescence for improved tumor immunotherapy
Liu, Z., Zuo, L., Zhou, Z., Liu, S., Ba, Y., Zuo, A., Ren, Y., Zhang, C., Chen, Y., Ma, H., et al. (2024) · MedComm · doi:10.1002/mco2.777 · Cited by 24
Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer
Sabatier, R., Nicolas, E., Paciencia, M., Jonville‐Béra, A. ‐., Madroszyk, A., Cécile, M., Braticevic, C., Duran, S., Tassy, L., Rouby, F., et al. (2018) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2018.02.011 · Cited by 24
The Role of Immunosenescence in Cerebral Small Vessel Disease: A Review
Cuore, A. D., Pacinella, G., Riolo, R., & Tuttolomondo, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137136 · Cited by 25
Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy
Mancuso, S., Mattana, M., Carlisi, M., Santoro, M., & Siragusa, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063368 · Cited by 27
Overcoming Barriers of Age to Enhance Efficacy of Cancer Immunotherapy: The Clout of the Extracellular Matrix
Owyong, M., Efe, G., Owyong, M., Abbasi, A. J., Sitarama, V., & Plaks, V. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00019 · Cited by 24
Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients
Kasanen, H. H. E., Hernberg, M., Mäkelä, S., Brück, O. E., Juteau, S., Kohtamäki, L. M., Ilander, M. M., Mustjoki, S. M., & Kreutzman, A. S. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02497-9 · Cited by 22
Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer
Zhang, S., Pease, D. F., Kulkarni, A. A., Kumar, M., Shanley, R., Xu, B., Joshi, S. P., & Patel, M. R. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/11795549211004489 · Cited by 22
Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults
Elias, R., Morales, J. K., & Presley, C. J. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0619-0 · Cited by 22
Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma
Leroy, V., Gerard, É., Dutriaux, C., Prey, S., Gey, A., Mertens, C., Beylot-Barry, M., & Pham‐Ledard, A. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02298-9 · Cited by 22
Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies
Sakakida, T., Ishikawa, T., Uchino, J., Tabuchi, Y., Komori, S., Asai, J., Arai, A., Tsunezuka, H., Kosuga, T., Konishi, H., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11875 · Cited by 21
Cancer Prevention and Treatment by Wholistic Nutrition.
Campbell, T. C. (2017) · PubMed · Cited by 20
Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study
Kleemann, J., Jäger, M., Valesky, E. M., Kippenberger, S., Kaufmann, R., & Meißner, M. (2021) · Cancer Management and Research · doi:10.2147/cmar.s286917 · Cited by 19
Immunotherapy in Older Adults: A Checkpoint to Palliation?
Elias, R., & Odejide, O. O. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238795 · Cited by 19
Safety and Effectiveness of Immune Checkpoint Inhibitors in Older Patients with Cancer: A Systematic Review of 48 Real-World Studies
Luciani, A., Ghidini, A., Dottorini, L., & Petrelli, F. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00899-7 · Cited by 19
The Epithelial–Mesenchymal Transition Influences the Resistance of Oral Squamous Cell Carcinoma to Monoclonal Antibodies via Its Effect on Energy Homeostasis and the Tumor Microenvironment
Bai, Y., Sha, J., Okui, T., Moriyama, I., Ngo, H. X., Tatsumi, H., & Kanno, T. (2021) · Cancers · doi:10.3390/cancers13235905 · Cited by 18
Treatment of Urothelial Cancer in Elderly Patients: Focus on Immune Checkpoint Inhibitors
Jodon, G., Fischer, S. M., & Kessler, E. R. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0540-8 · Cited by 17
The Aging-Related Prognostic Signature Reveals the Landscape of the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma
Chen, F., Gong, X., Meng, X., Feng, Y., Wu, J., Yu, C., & Li, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.857994 · Cited by 17
Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis
Deng, R., Zhang, H., Li, Y., & Shi, Y. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000442 · Cited by 17
Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer
Yang, Z., Chen, Y., Wang, Y., Hu, M., Qian, F., Zhang, Y., Zhang, B., Zhang, W., & Han, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.807575 · Cited by 17
Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy
Pradeep, J., Win, T. T., Aye, S. N., & Sreeramareddy, C. T. (2022) · Journal of Cancer · doi:10.7150/jca.72210 · Cited by 17
Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study
Bassanelli, M., Ricciuti, B., Giannarelli, D., Cecere, F. L., Roberto, M., Giacinti, S., Barucca, V., Santarelli, M., Ruggeri, E. M., Marchetti, P., et al. (2021) · Tumori Journal · doi:10.1177/03008916211004733 · Cited by 16
Considerations and Challenges in the Management of the Older Patients with Gastric Cancer
Loizides, S., & Papamichael, D. (2022) · Cancers · doi:10.3390/cancers14061587 · Cited by 16
The impact of smoking on the effectiveness of immune checkpoint inhibitors — a systematic review and meta-analysis
Lee, K., Lord, S. J., Kasherman, L., Marschner, I. C., Stockler, M. R., Gralla, R. J., Yang, J. C., Mok, T. S. K., & Lee, C. K. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1670354 · Cited by 16
Inhibitory Immune Checkpoint Molecule Expression in Clinical Sepsis Studies: A Systematic Review
Busch, L. M., Sun, J., Eichacker, P. Q., & Torabi‐Parizi, P. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004496 · Cited by 15
Drug-eluting beads bronchial arterial chemoembolization/bronchial arterial infusion chemotherapy with and without PD-1 blockade for advanced non-small cell lung cancer: a comparative single-center cohort study
Xu, S., Li, Y., Bie, Z., & Li, X. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-23-287 · Cited by 15
Immunotherapy in Older Patients with Cancer: A Narrative Review
Smith, A., Boby, J. M., Benny, S. J., Ghazali, N., Vermeulen, E. T., & George, M. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s435001 · Cited by 15
Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma
Zhao, B., Zhao, H., & Zhao, J. (2018) · International Journal of Cancer · doi:10.1002/ijc.31813 · Cited by 15
Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?
Al‐Mansour, Z., Pang, L., & Bathini, V. G. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0619-2 · Cited by 15
Age-related efficacy of immunotherapies in advanced non-small cell lung cancer: a comprehensive meta-analysis
Ding, Y., Lei, S., Wang, L., Tang, L., Zhang, Y., Liao, Y., Deng, X., Li, Y., Gong, Y., & Li, Y. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107925 · Cited by 16
Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years
Petrelli, F., Inno, A., Ghidini, A., Gori, S., & Bersanelli, M. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02779-2 · Cited by 15
Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry
Jochems, A., Bastiaannet, E., Aarts, M. J. B., van Akkooi, A. C. J., van den Berkmortel, F. W. P. J., Boers‐Sonderen, M. J., van den Eertwegh, A. J. M., de Glas, N. A., de Groot, J. W. B., Haanen, J. B. A. G., et al. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.04.006 · Cited by 14
Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature
de la Fouchardière, C., Decoster, L., Samalin, E., Terret, C., Kenis, C., Droz, J., Coutzac, C., & Smyth, E. C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102289 · Cited by 13
Efficacy of Immune Checkpoint Inhibitors in Cancer Patients of Different Ages: A Meta-Analysis
Li, J., & Gu, J. H. (2019) · Future Oncology · doi:10.2217/fon-2019-0279 · Cited by 13
Efficacy and safety profile of avelumab monotherapy
Zhao, B., Gao, M., Zhao, H., Zhao, J., & Shen, X. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103464 · Cited by 12
Immunosenescence and immunotherapy in older NSCLC patients
Zhang, J., Zhao, L., Li, H., Jia, Y., & Kong, F. (2024) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1523_23 · Cited by 12
Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma
Zhang, D., Zhu, Y., Shen, Z., Ma, S., Liu, S., & Lu, Z. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.02.010 · Cited by 12
Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD‐1/PD‐L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta‐Analysis
Wei, Y., Li, Y., Du, Q., Peng, X., Jin, J., Guo, H. Y., Li, Y., & Li, Q. (2020) · Journal of Immunology Research · doi:10.1155/2020/5269787 · Cited by 10
Single cell–resolved cellular, transcriptional, and epigenetic changes in mouse T cell populations linked to age-associated immune decline
He, J., Burova, E., Taduriyasas, C., Ni, M., Adler, C., Wei, Y. Z., Negron, N., Xiong, K., Bai, Y., Shavlakadze, T., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2425992122 · Cited by 11
Polymorbidity, ageing of immune system and low-grade systemic inflammation: a challenge for modern medicine
Shirinsky, V. S., & Shirinsky, I. V. (2020) · Medical Immunology (Russia) · doi:10.15789/1563-0625-pao-2042 · Cited by 13
Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers
Li, M., Kaili, D., & Shi, L. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v14.i1.19 · Cited by 12
The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
Spagnuolo, A., & Gridelli, C. (2023) · Cancers · doi:10.3390/cancers15082319 · Cited by 13
Disparity in Outcomes of Melanoma Adjuvant Immunotherapy by Demographic Profile
Ikeguchi, A. P., Machiorlatti, M. G., & Vesely, S. K. (2020) · Melanoma Management · doi:10.2217/mmt-2020-0002 · Cited by 10
Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: An observational study
Storm, B. N., Kalkhoran, H. A., Wilms, E. B., Brocken, P., Codrington, H., Houtsma, D., Portielje, J. E. A., de Glas, N. A., van der Ziel, D., van den Bos, F., et al. (2022) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2022.05.013 · Cited by 11
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response
Carey, A. E., & Weeraratna, A. T. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108698 · Cited by 10
Financial Toxicity: Management as an Adverse Effect of Cancer Treatment
Fessele, K. L. (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.762-764 · Cited by 9
Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany
Singh, P., McDonald, L., Waldenberger, D., Welslau, M., von der Heyde, E., Gauler, T. C., & Dietz, A. (2021) · Head & Neck · doi:10.1002/hed.26853 · Cited by 9
Identification of Aging‐Related Genes Associated with Prognostic Value and Immune Microenvironment Characteristics in Diffuse Large B‐Cell Lymphoma
Luo, C., Nie, H., & Yu, L. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3334522 · Cited by 9
Immune checkpoint inhibitor toxicity and associated outcomes in older patients with cancer
Hayashi‐Tanner, Y., Polewski, P. J., Gaddam, M., Fisher, N. R., Kovacs, A. J., & Marinier, D. E. (2022) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2022.05.007 · Cited by 9
Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guérin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Research Group JUOG-UC-1901-BCG
Inoue, T., Miyake, M., Nishimura, N., Onozawa, M., Kashima, S., Numakura, K., Narita, S., Iida, K., Uemura, M., Matsushita, Y., et al. (2022) · Urology · doi:10.1016/j.urology.2022.05.034 · Cited by 9
T-cell senescence: Unlocking the tumor immune “Dark Box” - A multidimensional analysis from mechanism to tumor immunotherapeutic intervention
Cheng, J., Zheng, J., Ma, C., Li, Y., & Hao, H. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.05.010 · Cited by 8
Immune Checkpoint Inhibitors in the Treatment of Advanced Melanoma in Older Patients: An Overview of Published Data
Lens, M. B., & Schachter, J. (2025) · Cancers · doi:10.3390/cancers17111835 · Cited by 11
Efficacy of PD-1/PD-L1 Plus CTLA-4 Inhibitors in Solid Tumors Based on Clinical Characteristics: a Meta-Analysis
Huo, G., Liu, W., Zhang, S., & Chen, P. (2023) · Immunotherapy · doi:10.2217/imt-2022-0140 · Cited by 9
Steroidogenic acute regulatory protein mediated variations of gender-specific sex neurosteroids in Alzheimer’s disease: Relevance to hormonal and neuronal imbalance
Manna, P. R., Yang, S., Manna, C., Waters, H., Islam, M. A., Reddy, A. P., Rawat, P., & Reddy, P. H. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105969 · Cited by 7
Targeting Aging Hallmarks with Monoclonal Antibodies: A New Era in Cancer Immunotherapy and Geriatric Medicine
Bo, M. D., Gambirasi, M., Vruzhaj, I., Cecchin, E., Pishdadian, A., Toffoli, G., & Safa, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26114982 · Cited by 8
Blood based immune biomarkers associated with clinical frailty scale in older patients with melanoma receiving checkpoint inhibitor immunotherapy
Hoi, E. T. V., Santegoets, S. J. A. M., Mooijaart, S. P., van Heemst, D., Özkan, A., Verdegaal, E. M. E., Slingerland, M., Kapiteijn, E., van der Burg, S. H., Portielje, J. E. A., et al. (2024) · Immunity & Ageing · doi:10.1186/s12979-024-00463-y · Cited by 7
Personal and clinical characteristics associated with immunotherapy effectiveness in stage IV non-small cell lung cancer
Patel, K. H., Alpert, N., Tuminello, S., & Taioli, E. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-682 · Cited by 7
Evaluating the potential of immunotherapy and chemoimmunotherapy in the treatment of elderly non-small cell lung cancer patients: A real-world study
Endo, S., Honda, T., Sato, K., Kubota, N., Kamoshida, T., Mochizuki, A., Fujii, M., Ochi, J., Miyazaki, Y., & Tsukada, Y. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100755 · Cited by 7
Nanoparticle-mediated delivery of herbal-derived natural products to modulate immunosenescence-induced drug resistance in cancer therapy: a comprehensive review
Yang, L., Wu, W. D., Yang, J., & Xu, M. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1567896 · Cited by 8
Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?
Wu, Q., Luo, S., & Xie, X. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000426 · Cited by 6
Efficacy of Pd-1/Pd-L1 Inhibitors in Advanced Gastroesophageal Cancer Based on Characteristics: A Meta-Analysis
Liu, W., Huo, G., & Chen, P. (2023) · Immunotherapy · doi:10.2217/imt-2022-0305 · Cited by 7

Authors: Elias, R., Karantanos, T., Sira, E., & Hartshorn, K. L.
Affiliations: Boston University (US)
New York Medical College (US)
Corresponding author: Elias, Rawad
ORCID: Elias, Rawad
Karantanos, Theodoros
Hartshorn, Kevan L.
Venue: Journal of Geriatric Oncology
Publisher: Elsevier BV
Published: 2017-05
Volume: 8
Issue: 3
Pages: 229-235
ISSN: 1879-4068 (ISSN-L)
DOI: 10.1016/j.jgo.2017.02.001
OpenAlex: W2588635414
Cited by: 133
References: 126
Citations by year: 2026: 3 · 2025: 12 · 2024: 13 · 2023: 11 · 2022: 20 · 2021: 18 · 2020: 18 · 2019: 17 · 2018: 16 · 2017: 5
FWCI: 1.60
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Geriatric Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: immune checkpoint inhibitors, immunosenescence, older adults, cancer immunotherapy, mechanism of action
MeSH terms: Age Factors, Aged, Aging, Antibodies, Monoclonal, Humans, Immunologic Factors, Immunotherapy, Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immunotherapy comes of age: Immune aging & checkpoint inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks